![[Podcast] Trial Trailblazers: Behind clinical breakthroughs](https://imgproxy.divecdn.com/cr_gUY8HHfHKWVfM5mEkCyXB9OzVqKd0L_Zq5ZJQSoM/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlX1BvZGNhc3RfY292ZXIxMzQ2eDcyOV9SMi5wbmc=.webp)
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high cholesterol.
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high cholesterol.
